GEN Exclusives

More »

GEN News Highlights

More »
Jul 27, 2009

Cryopraxis to Assess Cryo-Cell's Menstrual Stem Cell Technology for Diagnosing Endometriosis

  • Cryopraxis Cryobiology plans on evaluating the use of Cryo-Cell’s C’elle menstrual stem cell (MenSCs) technology in the diagnosis of endometriosis and treatment of stress urinary incontinence.

    The collaboration will investigate whether analysis of menstrual blood stem cells collected using Cryo-Cell’s system can accurately diagnose endometriosis. Cryopraxis will also investigate the potential for developing a treatment for urinary stress incontinence based on the injection of contractile menstrual stem cells into the urethra, to help restore the contractility of muscles and sphincters.

    The diagnosis of endometriosis currently requires laparoscopic procedures, whereas a stem cell-based diagnostic would be both noninvasive and cost-effective, according to Eduardo Cruz, founder and CEO of Cryopraxis. “This research will determine if the stem cells found in menstrual blood can accurately provide a diagnosis that is highly precise”. 

    Introduced in November 2007, Cryo-Cell’s C’elle service allows the collection and cryopreservation of menstrual flow containing undifferentiated adult stem cells for potential future use in regenerative therapeutics. Cryopraxis is a dedicated stem cell and tissue banking company, which reportedly operates the largest cryogenic storage facility and umbilical cord blood bank in Brazil and one of the largest cryogenic storage facilities in the world. 

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?